The role of interval debulking surgery in ovarian cancer.
- 1 November 2003
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 5 (6) , 473-481
- https://doi.org/10.1007/s11912-003-0008-8
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancerZeitschrift für Krebsforschung und Klinische Onkologie, 2002
- Splenectomy and Surgical Cytoreduction for Ovarian CancerGynecologic Oncology, 2000
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Stage IV Ovarian Cancer: Impact of Surgical Debulking1Gynecologic Oncology, 1997
- Prognostic Significance of Residual Disease in Patients with Stage IV Epithelial Ovarian CancerGynecologic Oncology, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- The Influence of Tumor Grade, Distribution, and Extent of Carcinomatosis in Minimal Residual Stage III Epithelial Ovarian Cancer after Optimal Primary Cytoreductive SurgeryGynecologic Oncology, 1994
- Peritoneal Implant Elimination during Cytoreductive Surgery for Ovarian Cancer: Impact on SurvivalGynecologic Oncology, 1993
- Long-term survival in ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Aggressive chemosurgical debulking in patients with advanced ovarian cancerGynecologic Oncology, 1990